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MaBACKGROUND Beta-blocker therapy after acute myocardial infarction (MI) improves survival. Beta-blocker doses used
in clinical practice are often substantially lower than those used in the randomized trials establishing their efﬁcacy.
OBJECTIVES This study evaluated the association of beta-blocker dose with survival after acute MI, hypothesizing that
higher dose beta-blocker therapy will be associated with increased survival.
METHODS A multicenter registry enrolled 7,057 consecutive patients with acute MI. Discharge beta-blocker dose was
indexed to the target beta-blocker doses used in randomized clinical trials, grouped as >0% to 12.5%, >12.5% to 25%,
>25% to 50%, and >50% of target dose. Follow-up vital status was assessed, with the primary endpoint of time-to-
death right-censored at 2 years. Multivariable and propensity score analyses were used to account for group differences.
RESULTS Of 6,682 patients with follow-up (median 2.1 years), 91.5% were discharged on a beta-blocker (mean dose
38.1% of the target dose). Lower mortality was observed with all beta-blocker doses (p < 0.0002) versus no beta-
blocker therapy. After multivariable adjustment, hazard ratios for 2-year mortality compared with the >50% dose were
0.862 (95% conﬁdence interval [CI]: 0.677 to 1.098), 0.799 (95% CI: 0.635 to 1.005), and 0.963 (95% CI: 0.765 to
1.213) for the >0% to 12.5%, >12.5% to 25%, and >25% to 50% of target dose groups, respectively. Multivariable
analysis with an extended set of covariates and propensity score analysis also demonstrated that higher doses were not
associated with better outcome.
CONCLUSIONS These data do not demonstrate increased survival in patients treated with beta-blocker doses
approximating those used in previous randomized clinical trials compared with lower doses. These ﬁndings provide the
rationale to re-engage in research to establish appropriate beta-blocker dosing after MI to derive optimal beneﬁt from
this therapy. (The PACE-MI Registry Study—Outcomes of Beta-blocker Therapy After Myocardial Infarction [OBTAIN]:
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1432beta-blockers or doses, basic evidence-based
medicine principles support the use of beta-
blockers that have been studied in trials at
the doses used or targeted; trials that report
dosing indicate that the majority of patients
achieved target doses. However, doses of
clinically used beta-blocker are substantially
lower (8,9). The impact of this large-scaleunderdosing of beta-blockers on the beneﬁcial effects
of beta-blocker therapy is unknown. Analyses of post-
MI beta-blocker trials have related mortality reduc-
tion to heart rate reduction (10,11); because heart
rate reduction is dose dependent, this supports the
notion that there could be a dose-dependent reduc-
tion in mortality. The OBTAIN (Outcomes of Beta-
blocker Therapy After Myocardial Infarction) study
is an observational multicenter registry in which
beta-blocker dosing information was collected in all
patients with acute MI at participating centers to
assess the effect of dose on survival. The OBTAIN hy-
pothesis was that higher dose beta-blocker therapy is
associated with increased survival.SEE PAGE 1442METHODS
STUDY DESIGN AND OVERSIGHT. Initiated in 2007,
OBTAIN was a companion registry to the PACE-MI
(PACEmaker and ß-Blocker Therapy Post-Myocardial
Infarction) trial (12). Detailed information on beta-
blocker dosing was collected in the registry. There
were 26 participating centers in the United States and
1 in Canada. When the trial was terminated in 2009, it
was noted that beta-blocker utilization was nearly
universal, but that most patients were treated with
doses#25% of the target doses used in clinical trials. At
that time, the decision was made to continue the reg-
istry and evaluate vital status for at least 2 years to
test the hypothesis that there is a dose–response
relationship in the beneﬁcial effect of beta-blocker
therapy on survival. After protocol modiﬁcation to
include vital status assessment and resubmission for
institutional review board approval, 21 of the original
sites continued their participation (including 92%
of the registry patients). An additional 5 U.S. sites
were recruited.
The study was funded by the National Heart, Lung,
and Blood Institute, and an observational study
monitoring board, appointed by the institute, moni-
tored study conduct. The study was approved by each
site’s institutional review board with a waiver of
consent for registry enrollment. Participating centers
and study committees and personnel are listed in the
Online Appendix.PATIENTS. Consecutive patients admitted with acute
MI at participating sites were entered into the regis-
try. Acute MI was diagnosed by: 1) either creatine
kinase elevation >2 times or troponin elevation >3
times the upper limit of normal; and 2) either chest
pain (or equivalent symptoms suggestive of MI) or
electrocardiographic changes consistent with MI.
Basic demographic, historical, and hospitalization
information, as well as information regarding the
index MI, was collected. Discharge beta-blocker type
and dose were recorded. All data were collected at
the site, and deidentiﬁed patient information was
entered in aWeb-based electronic data capture system.
BETA-BLOCKER DOSING. Beta-blocker type and dose
were chosen by the managing physician. For the
purposes of the present study, target doses for the
most commonly used beta-blockers were as follows:
metoprolol 200 mg/day (13,14); carvedilol 50 mg/day
(15) (Coreg CR [GlaxoSmithKline Pharmaceuticals,
Philadelphia, Pennsylvania]–equivalent dose 80 mg/
day); propranolol 180 mg/day (16); timolol 20 mg/day
(17); bisoprolol 10 mg/day (18); and atenolol 100 mg/
day (19). On the basis of the dose administered, a
proportion of the target dose was calculated (admin-
istered/target dose) only for patients taking 1 of these
beta-blockers. Beta-blocker doses were divided into 5
pre-speciﬁed groups: no beta-blocker, >0% to 12.5%,
>12.5% to 25%, >25% to 50%, and >50% of the target
dose.
STUDY ENDPOINT. The pre-speciﬁed endpoint for
this study was time to all-cause mortality with sur-
vival right-censored at 2 years. Vital status was
assessed by use of chart review, the Social Security
Administration’s Death Master File, or direct
communication with the patient/family. Per protocol,
vital status was assessed 1 and 2 years after MI.
Follow-up using the Social Security Administration’s
Death Master File incorporated a 6-month delay to
account for the lag time in recording deaths. A longer
term follow-up (>3 years) was available, particularly
for sites that participated in the original registry.
STATISTICAL ANALYSIS. Patient characteristics were
summarized as mean  SD or count (%). Differences
among groups were compared by using chi-square
tests for categorical variables and analysis of vari-
ance for continuous variables. Distribution-free rank
sum tests were used for variables that deviated from
normality. The median (interquartile range) was used
to summarize these variables. The Kaplan-Meier
method was used to calculate 1-, 2-, and 3-year sur-
vival in each study group.
Pre-speciﬁed analysis of the effect of the 5 pre-
speciﬁed groups on 2-year survival was tested
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1433by comparing Kaplan-Meier survival curves with a
log-rank test. Cox proportional hazards regression
was used to test for the independent effects of
beta-blocker dosing on survival. The following
pre-speciﬁed patient characteristics were used in
multivariable adjustment: age, sex, white race, His-
panic ethnicity, cardiac enzymes, left ventricular
ejection fraction, diabetes, hypertension, hypercho-
lesterolemia, ST-segment elevation MI, thrombolytic
therapy, primary percutaneous coronary interven-
tion, length of stay, and other discharge medica-
tions (aspirin, angiotensin-converting enzyme [ACE]
inhibitors/angiotensin receptor blockers, and statins).
A pre-speciﬁed secondary analysis was performed
comparing the outcomes for low-dose (#25%) and
high-dose ($50%) beta-blocker therapy.
Further sensitivity analyses of the effect of the 4
beta-blocker doses on outcome included evaluation of
3-year outcomes. Multivariable analysis included an
expanded set of all covariates listed in Table 1, in-
cluding use of carvedilol versus metoprolol. Random
effects (shared frailty model) were also included
for each of the recruiting hospitals to better model
differences in mortality among them. Quadratic and
cubic polynomial terms for continuous predictors
were included to account for potential nonlinearity.
Propensity score analysis was also performed as an
alternative adjustment for patient differences in the 4
beta-blocker dose groups. To calculate the propensity
score, we used mixed effects linear regression with
random effects of the recruiting centers, continuous
discharge beta-blocker dose (percentage of target
dose) as a dependent variable, and the expanded
control variable set reported in Table 1 (including
quadratic and cubic polynomial terms for continuous
predictors). Thus, the propensity scores represent
the predicted discharge beta-blocker dose, given
the extended set of patient characteristics. The
propensity score was used as a control variable in
the proportional hazards frailty regression model.
Further details are provided in the Online Appendix.
All tests were 2-tailed, and a conventional 5% sig-
niﬁcance level was used. A gatekeeper hypothesis
strategy for type I error control was used for pre-
speciﬁed study endpoints; alpha levels were to be
adjusted for subsequent tests if the gatekeeper null
hypothesis was rejected. Analyses were performed by
using SAS version 9.4 (SAS Institute, Inc., Cary, North
Carolina).
RESULTS
The registry included 7,057 patients. In-hospital
mortality was 4.7%, and 43 patients were lost tofollow-up. Table 1 displays baseline characteristics
of the 6,682 patients discharged alive, stratiﬁed ac-
cording to beta-blocker use. The mean age across
groups was 63 to 65 years, with male predominance.
Small to moderate group differences were noted for
most characteristics.
Discharge therapy included beta-blockers (91.5%),
aspirin (92.6%), ACE inhibitors/angiotensin receptor
blockers (66.3%), and statins (86.3%). There were 567
patients (8.5%) discharged without beta-blocker
therapy. Reasons provided for not administering
beta-blockers included low blood pressure (26%),
conduction system disease (16%), pulmonary disease
(17%), heart failure (9%), drug use (5%), debilitation
(5%), and other (22%).
Beta-blockers administered at discharge included
metoprolol (67.7%), carvedilol (24.3%), atenolol
(3.8%), bisoprolol (2.8%), propranolol (0.2%), and
others (1.1%). Of the patients discharged on a beta-
blocker, 24.0%, 37.2%, 25.5%, and 13.4% received
>0% to 12.5%, >12.5% to 25%, >25% to 50%, and >50%
of the target dose, respectively. The mean adminis-
tered dose was 38.1% of the target dose. Median
follow-up was 2.1 years (interquartile range: 2.0 to 2.5
years). At last follow-up (n ¼ 3,581), 52.4%, 20.2%, and
20.2% were taking the same, a higher, or a lower dose,
respectively, with a 3.8% discontinuation rate and a
3.4% initiation rate in patients not discharged on
beta-blockers. From discharge to 1 year, of the patients
treated with >12.5% to 25% of the target dose, only 4%
were subsequently in the >50% of the target dose
group. Of the patients treated with >50% of the target
dose, only 12% were subsequently treated with #25%
of the target dose. In this cohort, beta-blocker therapy
was associated with an unadjusted 51% (adjusted
45%; 95% conﬁdence interval [CI]: 33% to 55%) lower
mortality compared with no beta-blocker therapy.
At 2 years, there were a total of 831 deaths (post-
discharge mortality of 12.4%). The Central Illustration
(panel A) displays the Kaplan-Meier curves for the
primary analysis. Tables 2 and 3 provide the hazard
ratios (HRs) relative to no beta-blocker use and to the
>50% target dose. Multivariable analysis identiﬁed
that all tested parameters were independently related
to survival (Table 4). After the pre-speciﬁed multi-
variable adjustment, relative to the >50% target dose,
mortality did not differ for the >0% to 12.5% and
>25% to 50% doses, and was borderline statistically
signiﬁcant in those taking >12.5% to 25% of the target
dose but not after multivariable adjustment with the
extended set of covariates.
The Kaplan-Meier curves for low-dose (#25%)
versus high-dose ($50%) beta-blocker therapy (Central
Illustration, panel B) show a signiﬁcantly lower
TABLE 1 Characteristics of the Study Population and Mortality According to Beta-Blocker Dose
Discharge Beta-Blocker p Value
Beta-Blocker Dose
(% of the Target Dose) p Value
No,
n ¼ 567
(8.5%)
Yes,
n ¼ 6,115
(91.5%)
No Versus
Yes
>0%–12.5%,
n ¼ 1,448
(21.7%)
>12.5%–25%,
n ¼ 2,247
(33.6%)
>25%–50%,
n ¼ 1,541
(23.1%)
>50%,
n ¼ 809
(12.1%)
Among
5 Doses
Among 4
Beta-Blocker
Doses
Patient characteristics
Age, yrs 65.1  14.7 63.7  13.5 0.03 64.5  13.6 62.6  13.6 64.0  13.3 64.2  13.1 <0.0001 0.0001
Male 349 (61.6) 4,195 (68.6) 0.0006 971 (67.1) 1,555 (69.2) 1,056 (68.5) 570 (70.5) 0.004 0.35
Race 0.16 0.002 0.002
White 438 (77.2) 4,851 (79.3) 0.24 1,164 (80.4) 1,792 (79.8) 1,220 (79.2) 617 (76.3) 0.13 0.12
Black 69 (12.2) 654 (10.7) 0.28 116 (8.0) 226 (10.1) 185 (12.0) 120 (14.8) <0.0001 <0.0001
Asian 6 (1.1) 150 (2.5) 0.04 39 (2.7) 51 (2.3) 37 (2.4) 22 (2.7) 0.24 0.82
American Indian 3 (0.5) 26 (0.4) 0.73 6 (0.4) 11 (0.5) 8 (0.5) 1 (0.1) 0.68 0.52
Paciﬁc Islander 2 (0.4) 13 (0.2) 0.37 4 (0.3) 4 (0.2) 3 (0.2) 1 (0.1) 0.87 0.87
Unknown 50 (8.8) 428 (7.0) 0.11 120 (8.3) 164 (7.3) 91 (5.9) 49 (6.1) 0.04 0.05
Other 1 (0.2) 7 (0.1) 0.51 1 (0.1) 1 (0.0) 3 (0.2) 1 (0.1) 0.66 0.52
Hispanic 33 (6.4) 441 (7.7) 0.27 126 (9.5) 176 (8.4) 87 (6.0) 49 (6.3) 0.002 0.002
BMI, kg/m2 28.0  6.8 29.2  6.5 <0.0001 28.1  6.0 29.2  6.3 29.6  6.8 30.4  6.9 <0.0001 <0.0001
Medical history
Diabetes 152 (26.9) 1,985 (32.5) 0.006 399 (27.6) 688 (30.7) 533 (34.6) 336 (41.6) <0.0001 <0.0001
Hypertension 357 (63.1) 4,177 (68.4) 0.01 857 (59.2) 1,465 (65.3) 1,131 (73.4) 666 (82.4) <0.0001 <0.0001
Hyperlipidemia 276 (48.8) 3,336 (54.6) 0.008 723 (49.9) 1,154 (51.4) 893 (58.0) 523 (64.8) <0.0001 <0.0001
Previous MI 115 (20.3) 1,277 (20.9) 0.74 250 (17.3) 411 (18.3) 378 (24.6) 217 (26.9) 0.0000 <0.0001
CHF history 70 (12.4) 635 (10.4) 0.14 135 (9.3) 177 (7.9) 174 (11.3) 137 (17.0) <0.0001 <0.0001
CABG history 69 (12.2) 815 (13.3) 0.44 143 (9.9) 238 (10.6) 240 (15.6) 178 (22.0) <0.0001 <0.0001
ESRD 21 (3.7) 204 (3.3) 0.64 37 (2.6) 66 (2.9) 51 (3.3) 45 (5.6) 0.002 0.0009
CVA/TIA 58 (10.2) 640 (10.5) 0.86 133 (9.2) 199 (8.9) 183 (11.9) 115 (14.2) <0.0001 <0.0001
COPD 102 (18.0) 618 (10.1) <0.0001 150 (10.4) 222 (9.9) 150 (9.7) 83 (10.3) <0.0001 0.94
Current smoker 206 (36.9) 1,997 (33.1) 0.08 486 (33.9) 804 (36.2) 482 (32.0) 211 (26.5) <0.0001 <0.0001
ICD* 18 (3.2) 208 (3.4) 0.78 41 (2.8) 66 (2.9) 57 (3.7) 44 (5.4) 0.009 0.004
MI characteristics
STEMI 201 (35.4) 2,691 (44.0) 0.0001 717 (49.6) 1,002 (44.6) 651 (42.3) 297 (36.7) <0.0001 <0.0001
Anterior 60 (29.9) 904 (33.6) 0.28 247 (34.4) 311 (31.0) 231 (35.5) 108 (36.4) 0.17 0.16
Inferior/posterior 114 (56.7) 1,356 (50.4) 0.08 362 (50.5) 524 (52.3) 329 (50.5) 127 (42.8) 0.02 0.04
Thrombolytic therapy 25 (12.4) 365 (13.6) 0.65 79 (11.0) 146 (14.6) 105 (16.1) 32 (10.8) 0.03 0.02
Primary PCI 147 (73.1) 2,241 (83.3) 0.0002 630 (87.9) 864 (86.3) 526 (80.8) 203 (68.4) <0.0001 <0.0001
In-hospital revascularization
(nonprimary PCI and
CABG)
41 (20.4) 444 (16.5) 0.15 105 (14.6) 149 (14.9) 115 (17.7) 71 (23.9) 0.001 0.001
Diagnostic angiography 18 (9.0) 132 (4.9) 0.02 25 (3.5) 41 (4.1) 37 (5.7) 28 (9.4) <0.0001 0.0004
NSTEMI 366 (64.6) 3,424 (56.0) 0.0001 731 (50.5) 1,245 (55.4) 890 (57.8) 512 (63.3) <0.0001 <0.0001
Thrombolytic therapy 14 (3.8) 95 (7.5) 0.25 22 (3.0) 38 (3.1) 20 (2.2) 14 (2.7) 0.62 0.70
Primary PCI 126 (34.4) 1,409 (41.2) 0.01 334 (45.7) 565 (45.4) 333 (37.5) 159 (31.1) <0.0001 <0.0001
In-hospital revascularization
(nonprimary PCI and
CABG)
84 (23.0) 1,106 (32.3) 0.0002 233 (31.9) 409 (32.9) 292 (32.8) 164 (32.0) 0.006 0.96
Diagnostic angiography 72 (19.7) 508 (14.8) 0.01 97 (13.3) 168 (13.5) 143 (16.1) 91 (17.8) 0.008 0.05
Admission SBP, mm Hg 133.3  31.2 141.0  29.7 <0.0001 135.8  27.5 140.1  28.6 142.9  30.6 148.7  32.5 <0.0001 <0.0001
Admission heart rate,
beats/min
82.9  23.4 82.9  21.2 0.94 81.3  20.1 81.3  20.2 84.2  22.0 87.5  23.6 <0.0001 <0.0001
Heart failure on admission 71 (12.5) 616 (10.1) 0.07 167 (11.5) 179 (8.0) 150 (9.7) 112 (13.8) <0.0001 <0.0001
LVEF 48.8  14.5 46.7  12.8 0.001 45.3  13.6 47.6  12.4 46.4  12.6 47.2  12.8 <0.0001 <0.0001
Troponin, ng/ml 4.8 (1.3–21.6) 7.2 (2–28.1) <0.0001 12 (2.9–42.5) 7.2 (1.9–28.8) 6.2 (1.9–22.4) 4.3 (1.3–17.7) <0.0001 <0.0001
LOS, days 5 (3–9) 5 (4–8) 0.11 5 (4–8) 4 (3–7) 5 (4-8) 6 (4-10) <0.0001 <0.0001
Continued on the next page
Goldberger et al. J A C C V O L . 6 6 , N O . 1 3 , 2 0 1 5
Beta-Blockers After MI S E P T E M B E R 2 9 , 2 0 1 5 : 1 4 3 1 – 4 1
1434mortality with low-dose therapy compared with
high-dose therapy (HR: 0.758; 95% CI: 0.651
to 0.883; p ¼ 0.0004). After multivariable adjust-
ment (Table 4), there was lower mortality (HR:0.857; 95% CI: 0.734 to 1.002; p ¼ 0.05) with low-
versus high-dose therapy but not after multivariable
adjustment with the extended set of covariates
(Table 2).
TABLE 1 Continued
Discharge Beta-Blocker p Value
Beta-Blocker Dose
(% of the Target Dose) p Value
No,
n ¼ 567
(8.5%)
Yes,
n ¼ 6,115
(91.5%)
No Versus
Yes
>0%–12.5%,
n ¼ 1,448
(21.7%)
>12.5%–25%,
n ¼ 2,247
(33.6%)
>25%–50%,
n ¼ 1,541
(23.1%)
>50%,
n ¼ 809
(12.1%)
Among
5 Doses
Among 4
Beta-Blocker
Doses
Discharge medications
Beta-blocker dose, % target 12.0  1.7 25.0  0.4 49.1  3.2 100.3  29.0 <0.0001
Mode (% taking mode dose) 12.5 (92.4) 25 (99.6) 50 (93.1) 100 (59.8)
Metoprolol 923 (63.7) 1,645 (73.2) 1,052 (68.3) 522 (64.5) <0.0001
Carvedilol 505 (34.9) 468 (20.8) 340 (22.1) 174 (21.5) <0.0001
ASA 477 (84.1) 5,708 (93.3) <0.0001 1,352 (93.4) 2,099 (93.4) 1,450 (94.1) 745 (92.1) <0.0001 0.33
ACE-I/ARB 282 (49.7) 4,150 (67.9) <0.0001 899 (62.1) 1,541 (68.6) 1,084 (70.3) 581 (71.8) <0.0001 <0.0001
Statin 404 (71.8) 5,363 (87.8) <0.0001 1,246 (86.2) 2,003 (89.2) 1,330 (86.4) 726 (89.7) <0.0001 0.004
Clopidogrel 333 (58.7) 4,432 (72.5) <0.0001 1,034 (71.4) 1,654 (73.6) 1,118 (72.6) 573 (70.8) <0.0001 0.34
Dual antiplatelet 314 (55.4) 4,246 (69.4) <0.0001 997 (68.9) 1,580 (70.3) 1,074 (69.7) 546 (67.5) <0.0001 0.47
Mortality
1 yr (Kaplan-Meier %) 97 (17.1) 473 (7.7) <0.0001 117 (8.1) 142 (6.4) 136 (8.9) 69 (8.6) <0.0001 0.02
2 yrs (Kaplan-Meier %) 123 (21.7) 708 (11.7) <0.0001 165 (11.5) 212 (9.5) 197 (12.9) 118 (14.7) <0.0001 0.0002
3 yrs (Kaplan-Meier %) 133 (25.4) 795 (15.7) <0.0001 191 (16.2) 237 (12.2) 219 (17.6) 131 (20.6) <0.0001 <0.0001
Values are mean  SD, n (%), or median (interquartile range). *Includes patients with pre-admission ICD and those discharged with an ICD.
ACE-I ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; ASA ¼ aspirin; BMI¼ body mass index; CABG¼ coronary artery bypass graft surgery; CHF ¼ congestive heart failure;
COPD ¼ chronic obstructive pulmonary disease; CVA ¼ cerebrovascular accident; ESRD ¼ end-stage renal disease; ICD ¼ implantable cardioverter-deﬁbrillator; LOS ¼ length of stay; LVEF ¼ left ventricular
ejection fraction; MI ¼ myocardial infarction; NSTEMI ¼ non–ST-segment elevation myocardial infarction; PCI ¼ percutaneous coronary intervention; SBP ¼ systolic blood pressure; STEMI ¼ ST-segment
elevation myocardial infarction; TIA ¼ transient ischemic attack.
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1435Table 3 presents the multivariable HRs with
extended follow-up to 3 years (using the pre-speciﬁed
multivariable analysis) and the analyses focusing on
the 4 beta-blocker dose groups using multivariable
analysis with the expanded set of covariates (Table 5)
and the propensity score analysis. Relative to the
>50% dose group, there were no signiﬁcant differ-
ences between the >0% to 12.5% and >25% to 50%
dose groups. Although there were lower HRs in the
>12.5% to 25% dose group, these ﬁndings were not
consistently signiﬁcant across all analyses. Because
the >12.5% to 25% group was the largest and experi-
enced the lowest mortality, the HRs relative to the
>12.5% to 25% dose group were analyzed (Figure 1).
Increased HRs were noted in the >0% to 12.5% dose
group (expanded multivariable HR: 1.092; 95% CI:
0.896 to 1.331; p ¼ 0.38; propensity score HR: 1.394;
95% CI: 1.148 to 1.692; p ¼ 0.0008) and the >25% to
50% dose group (expanded multivariable HR: 1.176;
95% CI: 0.973 to 1.420; p ¼ 0.09; propensity score HR:
1.248; 95% CI: 1.035 to 1.505; p ¼ 0.02).
Subgroup analyses were performed for patients
taking metoprolol versus carvedilol, for those with ST-
segment elevation MI versus non–ST-segment eleva-
tion MI, patients with left ventricular ejection fraction
above or below 40%, and patients who were or were
not revascularized during their admission (primary
percutaneous coronary intervention, later percuta-
neous coronary intervention, or surgery). There was a
signiﬁcant interaction with the effect of beta-blockerdose only for revascularization (p ¼ 0.037). In patients
undergoing revascularization, the HRs compared with
the >50% dose were 0.649 (95% CI: 0.472 to 0.891),
0.546 (95%CI: 0.403 to 0.740), and0.768 (95%CI: 0.563
to 1.048) for the>0%to 12.5%,>12.5%to25%,and>25%
to 50% doses, respectively. In nonrevascularized pa-
tients, these effects were less pronounced (HR: 1.294;
95% CI: 0.940 to 1.782; HR: 0.963; 95% CI: 0.709 to
1.308; HR: 1.223; 95% CI: 0.901 to 1.660) for the >0% to
12.5%, >12.5% to 25%, and >25% to 50% doses.
DISCUSSION
The present study was designed to evaluate whether
higher dose beta-blocker therapy is associated with
increased survival compared with lower doses in
patients discharged from the hospital after MI. Con-
trary to our hypothesis, improved outcome with
higher dose beta-blocker therapy (speciﬁcally the
target beta-blocker doses used in previous random-
ized clinical trials) was not observed. Although
baseline differences in the treatment groups preclude
a deﬁnitive determination of the dose–response
relationship between beta-blocker dose and mor-
tality post-MI, the lowest observed mortality was at
25% of the target dose (i.e., metoprolol 50 mg/day).
However, there was no consistent statistically sig-
niﬁcant reduction in mortality with this dose with
the various analyses used to adjust for baseline dif-
ferences among the groups. In relation to these
CENTRAL ILLUSTRATION Beta-Blockers After MI: Unadjusted Kaplan-Meier Survival Curves for the 5 Discharge
Doses Analyzed and Low- and High-Dose Beta-Blocker Therapy
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Kaplan-Meier survival curves for (A) the primary (unadjusted) analysis comparing the 5 discharge doses (no beta-blocker and >0% to 12.5%,
>12.5% to 25%, >25% to 50%, and >50% of the target dose) of beta-blockers and (B) the secondary (unadjusted) analysis comparing
low-dose (#25% of the target dose) versus high-dose ($50% of the target dose) beta-blocker therapy. BB ¼ beta-blocker; MI ¼ myocardial
infarction.
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1436ﬁndings, the existing evidence base from random-
ized clinical trials incorporated primarily target doses
and provided no information regarding the dose–
response of post-MI beta-blocker therapy onsubsequent survival. Thus, the present registry data
remain consistent with prior clinical trials that re-
ported a beneﬁt of full-dose beta-blocker therapy.
However, they raise the question of whether lower
TABLE 2 Univariable and Multivariable Adjusted HRs for the Primary 5-Dose Analysis and the Secondary Analysis Comparing
Low (#25% of Target Dose) Versus High ($50% of Target Dose) Dose on the Basis of the Pre-Speciﬁed Analyses and Using the
Extended Set of Covariates
Pre-Speciﬁed Analyses
Extended Multivariable AnalysisUnivariable Multivariable
HR 95% CI p Value HR 95% CI p Value HR 95% CI p Value
Primary analysis
Versus no beta-blocker
>0%–12.5% (n ¼ 1,448) 0.486 0.385–0.614 <0.0001 0.530 0.418–0.673 <0.0001 0.576 0.379–0.877 0.01
>12.5%–25% (n ¼ 2,247) 0.395 0.316–0.493 <0.0001 0.492 0.392–0.617 <0.0001 0.562 0.374–0.843 0.005
>25%–50% (n ¼ 1,541) 0.547 0.437–0.685 0.0009 0.593 0.471–0.746 <0.0001 0.649 0.435–0.970 0.04
>50% (n ¼ 809) 0.626 0.487–0.806 0.002 0.615 0.475–0.797 0.0002 0.666 0.440–1.007 0.05
Versus >50%
>0%–12.5% 0.776 0.612–0.983 0.05 0.862 0.677–1.098 0.23 0.865 0.667–1.123 0.28
>12.5%–25% 0.630 0.503–0.789 <0.0001 0.799 0.635–1.005 0.05 0.843 0.664–1.071 0.16
>25%–50% 0.873 0.695–1.097 0.49 0.963 0.765–1.213 0.75 0.975 0.769–1.237 0.84
Secondary analysis
#25% versus $50% 0.758 0.651–0.883 0.0004 0.857 0.734–1.002 0.05 0.889 0.754–1.048 0.16
CI ¼ conﬁdence interval; HR ¼ hazard ratio.
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1437doses may result in equivalent outcomes compared
with the target dose. These data support the need for
further testing to determine optimal dosing of beta-
blockers after MI.
Because there are several potential explanations
for the results, these intriguing ﬁndings from the
registry require careful explication. First, it remains
possible, although unlikely, that target dose beta-
blocker therapy is still associated with better sur-
vival than lower doses; this would be possible in this
registry if some unmeasured confounder(s) were un-
equally represented in the target and lower dose
groups, making the former a substantially higher risk
group than the low-dose group in which accounting
for this parameter would substantially alter (reverse)
the estimates of the adjusted survival. It is more
feasible that further adjusting for other unmeasured
confounders would show that there is no strong dose
dependence of beta-blocker effect. In other words,
once a threshold dose is achieved, further increments
in the dose do not provide further beneﬁt. InTABLE 3 Sensitivity Analyses Showing Adjusted HRs for 3-Year Mort
Using the Pre-Speciﬁed MV Analysis, and the MV Analysis With the Ex
4 Beta-Blocker Dose Groups
Pre-Speciﬁed MV Analysis Ex
HR 95% CI p Value HR
>0%–12.5% 0.886 0.705–1.114 0.30 0.937
>12.5%–25% 0.792 0.638–0.984 0.04 0.866
>25%–50% 0.964 0.775–1.120 0.74 1.016
MV ¼ multivariable; other abbreviations as in Table 2.addition, the registry data are consistent with a
greater beneﬁt at lower doses than the target doses
used in the clinical trials, but this claim would need to
be tested prospectively. Finally, it is conceivable that
there is no single optimal dose for all post-MI pa-
tients, with some patients beneﬁting from lower
doses and some patients requiring higher doses.
Because the trial hypothesis was that higher doses
would be associated with improved outcomes, an a
priori noninferiority analysis was not proposed to
show noninferiority of the >12.5% to 25% target dose.
Although it would not be appropriate to conduct
noninferiority testing with a margin determined in a
post-hoc manner, our post-hoc calculations showed
that the noninferiority margin which would change
the conclusion regarding noninferiority of the >12.5%
to 25% target dose would have to be relatively small.
Further studies will need to determine whether ﬁxed
target dosing for all post-MI patients or individual-
ized dosing on the basis of patient or MI characteris-
tics will optimize outcomes.ality Compared With the >50% of Target Dose Group
tended Set of Covariates and Propensity Score Analysis for the
tended MV Analysis Propensity Score Analysis
95% CI p Value HR 95% CI p Value
0.730–1.202 0.61 1.163 0.910–1.486 0.23
0.688–1.091 0.22 0.834 0.664–1.047 0.12
0.809–1.275 0.89 1.041 0.832–1.302 0.73
TABLE 4 HRs and 95% CIs From MV Analysis of 2-Year Mortality in the 2 Pre-Speciﬁed
Analyzed Cohorts According to Predictor
5 Discharge Doses #25% Versus $50% of Target Dose
HR (95% CI) p Value HR (95% CI) p Value
Beta-blocker
dose
See Table 2 <0.001 0.857 (0.734–1.002) 0.05
Age 1.054 (1.048–1.060) <0.0001 1.057 (1.050–1.064) <0.0001
ln(troponin) 1.070 (1.023–1.119) 0.003 1.068 (1.018–1.121) 0.008
LVEF 0.980 (0.975–0.986) <0.0001 0.981 (0.975–0.987) <0.0001
ln(LOS) (days) 1.320 (1.188–1.467) <0.0001 1.312 (1.167–1.476) <0.0001
Male 1.240 (1.070–1.436) 0.004 1.213 (1.031–1.427) 0.02
White race 0.822 (0.698–0.969) 0.02 0.824 (0.688–0.988) 0.04
Hispanic
ethnicity
0.678 (0.496–0.926) 0.02 0.665 (0.479–0.924) 0.02
Diabetes 1.453 (1.256–1.680) <0.0001 1.550 (1.320–1.820) <.0001
Hypertension 1.313 (1.090–1.581) 0.004 1.275 (1.037–1.568) 0.02
Hyperlipidemia 0.815 (0.706–0.940) 0.005 0.811 (0.693–0.949) 0.009
STEMI 0.694 (0.575–0.837) 0.0001 0.690 (0.561–0.848) 0.0004
Thrombolytic
therapy
0.646 (0.445–0.937) 0.02 0.587 (0.381–0.905) 0.02
Primary PCI 0.614 (0.516–0.731) <0.0001 0.596 (0.492–0.721) <0.0001
ASA 0.599 (0.494–0.727) <0.0001 0.677 (0.539–0.849) 0.001
ACE-I/ARB 0.763 (0.662–0.878) 0.0002 0.810 (0.693–0.947) 0.008
Statin 0.752 (0.633–0.892) 0.001 0.818 (0.671–0.998) 0.05
Predictors were: 1) the 5 pre-speciﬁed dose groups (none, >0% to 12.5%, >12.5% to 25%, >25% to 50%,
and >50% of the target dose); and 2) the low-dose (#25% of target dose) and high-dose ($50% of the target
dose) groups. HRs for continuous variables are associated with 1 unit increase in the measure.
Abbreviations as in Tables 1 and 2.
TABLE 5 HRs and 95% CIs From the Multivariable Analysis With
the Extended Set of Covariates of 3-Year Mortality in the
4 Treated Beta-Blocker Dose Groups
HR (95% CI) p Value
Beta-blocker dose See Table 2
Age 1.529 (1.044–2.240) 0.03
Age (quadratic) 0.994 (0.989–1.000) 0.05
Age (cubic) 1.000 (1.000–1.000) 0.04
ln(troponin) (cubic) 1.006 (0.999–1.013) 0.09
ln(LOS) 2.838 (0.578–13.937) 0.20
Male 1.374 (1.170–1.615) 0.0001
Diabetes 1.370 (1.163–1.614) 0.0002
Hypertension 1.219 (0.999–1.487) 0.05
STEMI 0.842 (0.666–1.065) 0.15
Thrombolytic therapy 0.739 (0.498–1.098) 0.13
Primary PCI 0.580 (0.474–0.710) <0.0001
ASA 0.784 (0.625–0.984) 0.04
ACE-I/ARB 0.878 (0.754–1.023) 0.10
Statin 0.778 (0.632–0.958) 0.02
History of MI 1.200 (1.015–1.419) 0.03
History of CABG 1.285 (1.073–1.538) 0.006
In-hospital revascularization 0.526 (0.431–0.641) <0.0001
History of COPD 1.708 (1.411–2.066) <0.0001
History of ESRD 2.366 (1.836–3.049) <0.0001
History of CHF 1.327 (1.104–1.595) 0.003
History of CVA/TIA 1.256 (1.048–1.504) 0.01
ICD 1.360 (1.006–1.840) 0.05
BMI 0.745 (0.617–0.899) 0.002
BMI (quadratic) 1.007 (1.002–1.013) 0.01
BMI (cubic) 1.000 (1.000–1.000) 0.03
The 4 treated beta-blocker dose groups were as follows: >0% to 12.5%, >12.5%
to 25%, >25% to 50%, and >50% of the target dose.
BMI ¼ body mass index; other abbreviations as in Tables 1 and 2.
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1438A variety of data support the biologic plausibility
for the lack of a uniform improved survival with
target dose versus low-dose beta-blocker therapy
post-MI. Because most of the randomized clinical trial
data for the beneﬁcial effects of beta-blocker therapy
were derived before thrombolysis, primary angio-
plasty, and routine use of aspirin, statins, and ACE
inhibitors, the beneﬁt of beta-blockers in the modern
era has often been questioned. Meta-analyses
including >50,000 patients from the early random-
ized trials of post-MI beta-blocker therapy (1,2)
demonstrated 19% to 23% reductions in mortality.
The more contemporary CAPRICORN (Effect of Car-
vedilol on Outcome After Myocardial Infarction in
Patients With Left Ventricular Dysfunction) (15) ran-
domized trial of carvedilol in post-MI patients with a
left ventricular ejection fraction #40% also demon-
strated a 23% reduction in all-cause mortality.
Notably, in CAPRICORN, 74% of patients achieved the
target dose and an additional 11% achieved 50% of the
target dose. Large-scale observational studies (3–5)
from Medicare databases documented the beneﬁts
of beta-blocker therapy in an era of rampant under-
use. The largest contemporary trial, COMMIT (Clopi-
dogrel and Metoprolol in Myocardial Infarction Trial)
(20), randomized 45,852 patients with suspected
acute MI to receive metoprolol (initially intravenousfollowed by 200 mg orally daily) versus placebo
and noted no reduction in mortality at 28 days. A
2014 meta-analysis (21) comparing the effect of
beta-blockers on mortality after MI in the pre- versus
post-reperfusion eras noted no beneﬁt in the post-
reperfusion era. Finally, a contemporary observa-
tional report identiﬁed a 15% reduction in mortality
with beta-blocker therapy after MI (22). The changes
in the therapeutic landscape of MI care and the vari-
able reported outcomes provide further rationale to
re-explore the effect of beta-blocker treatment and
dosing on outcomes after MI.
Several studies (8,9) have noted beta-blocker
underdosing relative to clinical trial doses. There are
scant data overall and no randomized clinical trial
data addressing whether this represents an accept-
able or “poor” clinical practice. A 1998 retrospective
cohort study (23) of 1,165 post-MI patients, of whom
365 were treated with beta-blockers, is the only pre-
vious study evaluating the effect of dose on out-
come. Unadjusted mortality at a mean follow-up of
approximately 2 years in those treated with $50%
FIGURE 1 Adjusted Hazard Ratios for 3-Year Survival With Multivariable Analyses and
Propensity Score Analysis Relative to the >12.5% to 25% of Target Dose Group
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1439and <50% of the target dose was 6.9% and 3.4%,
respectively. Multivariable analysis demonstrated a
67% reduction in cardiovascular mortality associated
with low-dose beta-blockers. Interestingly, a study of
208 post-MI patients (24), of whom 154 were treated
with a mean beta-blocker dose of 34% of the target
dose, demonstrated a 60% reduction in all-cause
mortality at a mean follow-up of 58.5 months.
Because no previous randomized clinical trials eval-
uated whether low-dose or target dose beta-blocker
therapy results in improved outcomes after MI, the
OBTAIN registry establishes clinical equipoise for this
issue and justiﬁes further evaluation.
Dose-dependent effects of beta-blockers in the
setting of heart failure have been examined, with
somewhat inconsistent results (25–27). Whereas some
trials (26,27) have shown a direct relationship of dose
to survival, a meta-analysis (28) found no signiﬁcant
difference in mortality reduction between the trials in
which patients received $50% of the target dose
versus low doses (relative risk: 0.74 and 0.78,
respectively); a relationship to heart rate reduc-
tion was noted. Although there may be some com-
monality of purpose in the use of beta-blockers
post-MI and in heart failure, it is also possible that
the dose–response relationships are different, re-
ﬂecting important variations in underlying global and
regional autonomic abnormalities (particularly in the
degree of sympathoexcitation) between the 2 condi-
tions. Furthermore, it is possible that the dose–
response relationships for the beneﬁcial effects of
beta-blockers, even among subgroups of patients
with MI, may be ﬂatter than the dose–response re-
lationships for adverse effects, including those that
might affect the conduction system or cause meta-
bolic adverse effects (e.g., hyperlipidemia, insulin
resistance) (29).
The predominant mechanisms of the beneﬁt for
beta-blocker therapy after MI are reductions in
ischemia, reinfarction, and sudden death. In the era
of revascularization, aspirin, and statin use, it is
plausible that the contribution of beta-blocker ther-
apy to reductions in ischemia and reinfarction are not
as prominent as when the initial beta-blocker clinical
trials were performed. In fact, a 41% reduction in
sudden death was reported in a pooled analysis of
5 studies evaluating trials of metoprolol post-MI, ac-
counting for virtually all the difference in total mor-
tality between the patients receiving metoprolol and
placebo (30). Although it is possible that this beneﬁt
plays an even more prominent role in the modern era
of post-MI treatment, it is also interesting to note
that the presenting rhythms for out-of-hospital car-
diac arrest have undergone transformation over thelast decades, with a decline in ventricular ﬁbrilla-
tion and an increase in pulseless electrical activity/
asystole (31). The natural history of this change is
uncertain but may reﬂect, at least in part, the use of
beta-blockers. Of particular interest is a report that
noted an adjusted odds ratio of 5 for beta-blocker use
among out-of-hospital cardiac arrest survivors pre-
senting with pulseless electrical activity versus ven-
tricular ﬁbrillation (32). The potential importance of
bradyarrhythmias was further highlighted in the
CARISMA (Cardiac Arrhythmias and Risk Stratiﬁca-
tion After Acute Myocardial Infarction) study (33), in
which post-MI patients with a left ventricular ejection
fraction <40% received an implantable cardiac
monitor. At the 2-year follow-up, 17% of patients had
either high-degree atrioventricular block, signiﬁcant
sinus bradycardia, or sinus arrest.
Personal factors that might inﬂuence the optimal
beta-blocker dose include individual risk on the basis
of patient and MI characteristics, genetic poly-
morphisms, and observed beta-blocker effect. For
example, the OACIS (Osaka Acute Coronary Insufﬁ-
ciency Study) registry (34) noted improved survival
with beta-blocker therapy after ST-segment elevation
MI only in the higher risk subgroup. Some data
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: Therapy with beta-
adrenergic antagonist drugs is recommended for pa-
tients after MI, but the most commonly prescribed
doses are one-quarter of the dose evaluated in the
randomized clinical trials that demonstrated efﬁcacy,
and optimum doses have not been validated.
TRANSLATIONAL OUTLOOK: Additional research
is needed to compare various doses of beta-blockers
in survivors of MI and to identify factors that inﬂuence
optimum dose selection.
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1440suggest that beta-adrenergic receptor polymorphisms
inﬂuence outcomes in acute coronary syndromes and
heart failure (35–38), but the dose–response effect is
unknown. Furthermore, genetic polymorphisms may
affect beta-blocker metabolism and concentration
(39,40). A number of analyses have suggested that
mortality reduction post-MI is related more to the
degree of heart rate reduction than to the type of
beta-blocker (10,11). Whether these factors can allow
for optimal titration of beta-blocker dose for an in-
dividual post-MI patient requires further study.
There are several reasons for the current high rate
of low-dose beta-blocker therapy post-MI. This may
represent either physician or patient inertia. Some
patients may not be able to tolerate higher doses for
hemodynamic reasons or due to noncardiac adverse
effects or a more severe medical condition. Finally,
advanced conduction system or myocardial disease
may also preclude dose up-titration. There is no a
priori reason for these factors to bias toward greater
beneﬁt with lower doses.
STUDY LIMITATIONS. An important caveat for the
current ﬁndings is that they do not represent ran-
domized clinical trial results. As such, multiple beta-
blockers were used, and the doses were indexed to
doses used in clinical trials. Although this method
does not assure equivalent effects, it should be noted
that 93% of the treated patients in this registry
received either metoprolol or carvedilol, which was
accounted for in the sensitivity analyses. In addition,
the survival analysis was indexed to the discharge
beta-blocker dose. Although dose changes do occur
over time, only a minority of patients had their doses
up-titrated. Being a registry, there was also nonuni-
form distribution of risk factors among groups. In
addition, the speciﬁc rationale for the individual
dosing regimens is unknown. Thus, the multivari-
able/propensity score analyses may have incom-
pletely adjusted for these differences, and there may
be unmeasured covariates, such as the extent of
coronary artery disease or follow-up heart rate and
blood pressure, which could affect the ﬁndings.
However, multivariable adjustment and propensityscore analyses consistently showed no greater beneﬁt
with full-dose beta-blocker therapy, contrary to the
original hypothesis. Thus, despite these limitations, it
is apparent that there is a need to stimulate further
randomized trials of post-MI beta-blocker therapy
from their currently dormant state.
CONCLUSIONS
Current practice is characterized by the use of low-
dose beta-blocker therapy post-MI. To date, no data
support this practice, as all the randomized clinical
trials used higher target doses. Because these trials
did not include dose titration studies, the present
ﬁndings are not in conﬂict with the randomized
clinical trial data. Importantly, further research is
needed to establish optimal (personalized) beta-
blocker dosing after MI.
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